Development of a new nano-immune agonist to improve immunotherapy for melanoma, a challenging skin cancer, by changing the ...

In recent years, cell therapies have developed alongside chemotherapy and immunotherapy to become a new pillar in the ...

In recent years, cell therapies have developed alongside chemotherapy and immunotherapy to become a new pillar in the treatment of patients with blood and lymph gland cancer. In solid tumors, such as ...

NEW YORK – Seattle-based BrainChild Bio announced Friday that it is advancing its leading drug candidate, a CAR T-cell therapy targeting the immune checkpoint B7-H3 to a registrational trial, to ...